About Rocket Pharmaceuticals
Rocket Pharmaceuticals develops gene therapies for severe and rare inherited diseases, focusing on patients with limited treatment options. They use a platform called AAV (Adeno-Associated Virus) to deliver corrected genes directly into patients' bodies, targeting diseases that affect the heart, liver, eyes, or central nervous system. Unlike competitors, Rocket Pharmaceuticals emphasizes a patient-centric approach and collaborates with larger pharmaceutical companies to support their research and therapy development. Their mission is to create both the first and best gene therapies available, guided by values of Trust, Generosity, Curiosity, and Elevation.
Cranbury Township, New JerseyHeadquarters
2015Year Founded
$44MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees
Risks
Increased competition from New Jersey biotech companies like BioAegis Therapeutics.
Potential regulatory delays could impact treatment market timelines.
Recent stock offering may dilute shareholder value and affect investor confidence.
Differentiation
Rocket Pharmaceuticals focuses on gene therapy for rare and undertreated diseases.
The company uses lentiviral and AAV platforms for targeted gene delivery.
Their patient-centric approach aims to provide life-changing treatments for genetic disorders.
Upsides
EMA's acceptance of RP-L102 application boosts potential market entry in Europe.
Positive data from lentiviral portfolio suggests strong clinical efficacy and commercialization potential.
Strategic location in New Jersey offers access to industry leaders and partners.
Funding
Total raised$43.97 M
Latest valuation$125.50 M
StageIPO
POST IPO EQUITY
11/30/2024$165
GRANT
10/31/2020$4
EARLY VC
8/31/2017$25
$125.50 M